Stroke · 2023 · 16 citations · 10 references
Veterinary MedicineInfectious DiseasesClinical EpidemiologyImmunizationVaccinologyAdverse Events Following ImmunizationCerebrovascular DiseaseStrokeVaccinationVaccine EffectivenessVaccine SafetySars-cov-2 InfectionStroke HistorySubarachnoid Hemorrhage Complications
BACKGROUND: Whether the SARS-CoV-2 mRNA vaccines may cause a transient increased stroke risk is uncertain. METHODS: In a registry-based cohort of all adult residents at December 27, 2020, in Norway, we linked individual-level data on COVID-19 vaccination, positive SARS-CoV-2 test, hospital admissions, cause of death, health care worker status, and nursing home resident status extracted from the Emergency Preparedness Register for COVID-19 in Norway. The cohort was followed for incident intracerebral bleeding, ischemic stroke, and subarachnoid hemorrhage within the first 28 days after the first/second or third dose of mRNA vaccination until January 24, 2022. Stroke risk after vaccination relative to time not exposed to vaccination was assessed by Cox proportional hazard ratio, adjusted for age, sex, risk groups, health care personnel, and nursing home resident. RESULTS: The cohort included 4 139 888 people, 49.8% women, and 6.7% were ≥80 years of age. During the first 28 days after an mRNA vaccine, 2104 people experienced a stroke (82% ischemic stroke, 13% intracerebral hemorrhage, and 5% subarachnoid hemorrhage). Adjusted hazard ratios (95% CI) after the first/second and after the third mRNA vaccine doses were 0.92 (0.85-1.00) and 0.89 (0.73-1.08) for ischemic stroke, 0.81 (0.67-0.98) and 1.05 (0.64-1.71) for intracerebral hemorrhage, and 0.64 (0.46-0.87) and 1.12 (0.57-2.19) for subarachnoid hemorrhage, respectively. CONCLUSIONS: We did not find increased risk of stroke during the first 28 days after an mRNA SARS-CoV-2 vaccine.
10
Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text
Veterinary Medicine, Infectious Diseases, Preventive Medicine +17
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Noam Barda, Noa Dagan, Yatir Ben‐Shlomo et al. · New England Journal of Medicine · 2021 · 1.1K citations · Full text
Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Nicola P. Klein, Ned Lewis, Kristin Goddard et al. · JAMA · 2021 · 641 citations · Full text
Veterinary Medicine, Infectious Diseases, Preventive Medicine +17